Autoantibody Profile of Children with Juvenile Dermatomyositis.


Journal

Indian journal of pediatrics
ISSN: 0973-7693
Titre abrégé: Indian J Pediatr
Pays: India
ID NLM: 0417442

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 22 06 2020
accepted: 24 01 2021
pubmed: 12 3 2021
medline: 15 12 2021
entrez: 11 3 2021
Statut: ppublish

Résumé

To study autoantibody profile in juvenile dermatomyositis (JDM) and to look for phenotypic associations of these autoantibodies, if any. Thirty-four children with JDM with a minimum follow-up duration of 24 mo were enrolled. Clinical findings and investigations at the time of diagnosis were noted from the clinic records. At inclusion, they were clinically evaluated for residual disease, disease activity and complications. All the enrolled patients were tested for antinuclear antibodies (ANA), muscle specific antibodies (MSA) and myositis associated autoantibodies (MAA). ANA positivity was seen in 14/34 children. At least one MSA or MAA was present in 8/34 children. Anti-SRP, anti-MDA-5, and anti-Mi-2 antibodies were present in 4, 3, and 1 patient, respectively. Anti-SSA/Ro52 antibody was positive in 1 child. All four children with anti-SRP antibody were girls, who had polycyclic course. Two of them developed calcinosis. Prominent skin involvement with less severe muscle involvement and monocyclic course were seen in patients with anti-MDA-5 antibody. Two of them had arthritis/arthralgia at initial presentation. The only patient with anti-Mi-2 had normal muscle strength at enrollment. None of the patients had anti-synthetase antibodies (anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ), anti-Ku, anti-Scl-70, anti-NXP-2 or anti-HMG CoA. Eight patients tested positive for at least one MSA or MAA. The prevalence of autoantibodies was low. Positivity for anti-SRP, anti-MDA-5, anti-Mi-2 and anti-SSA/Ro52 antibodies was seen in 4, 3, 1 and 1 patients, respectively. Ethnic differences and testing for autoantibodies during/after therapy could be responsible for the low positivity rate for autoantibodies.

Identifiants

pubmed: 33694062
doi: 10.1007/s12098-021-03680-1
pii: 10.1007/s12098-021-03680-1
doi:

Substances chimiques

Antibodies, Antinuclear 0
Autoantibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1170-1173

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021. Dr. K C Chaudhuri Foundation.

Références

Li D, Tansley SL. Juvenile dermatomyositis—clinical phenotypes. Curr Rheumatol Rep. 2019;21:74.
doi: 10.1007/s11926-019-0871-4
Deakin CT, Yasin SA, Simou S, et al. Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis: prediction of outcomes in juvenile myositis. Arthritis Rheumatol. 2016;68:2806–16.
doi: 10.1002/art.39753
Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017;52:1–19.
doi: 10.1007/s12016-015-8510-y
Targoff IN, Miller FW, Medsger TA, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9:527–35.
doi: 10.1097/00002281-199711000-00008
Tansley SL, Simou S, Shaddick G, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun. 2017;84:55–64.
doi: 10.1016/j.jaut.2017.06.007
Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280:24–38.
doi: 10.1111/joim.12444
Pachman LM, Khojah AM. Advances in juvenile dermatomyositis: myositis specific antibodies aid in understanding disease heterogeneity. J Pediatr. 2018;195:16–27.
doi: 10.1016/j.jpeds.2017.12.053
Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford). 2014;53:2204–8.
doi: 10.1093/rheumatology/keu259
Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 2011;158:675–7.
doi: 10.1016/j.jpeds.2010.11.033
Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol. 2008;35:927–9.
pubmed: 18322984

Auteurs

Avinash Sharma (A)

Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.

Dharmagat Bhattarai (D)

Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.

Anju Gupta (A)

Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India. anjupgi@gmail.com.

Sandesh Guleria (S)

Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.

Amit Rawat (A)

Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.

Pandiarajan Vignesh (P)

Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.

Ravinder Garg (R)

Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.

Surjit Singh (S)

Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH